Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus
- 1 July 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 125 (1) , 149-154
- https://doi.org/10.1046/j.1365-2249.2001.01520.x
Abstract
Summary: Antiphospholipid antibodies (aPL), especially lupus anticoagulant (LAC), characterize systemic lupus erythematosus (SLE) patients at increased risk for arterial and venous thromboembolic complications. It has been reported that purified human anti-phospholipid antibodies cause endothelial cell activation in in vitro experiments. In order to investigate whether increased endothelial cell activation is associated with thromboembolic events in SLE patients with LAC, we measured plasma levels of thrombomodulin (TM), von Willebrand factor (vWf), sP-selectin, vascular cell adhesion molecule-1 (sVCAM-1) and ED1-fibronectin in a study of 76 patients with SLE. Patients were subdivided on the basis of: no history of thrombosis and LAC-negative (n = 22) or LAC-positive (n = 17); positive history of thrombosis and LAC-negative (n = 16) or LAC-positive (n = 21). The median SLE disease activity index (SLEDAI) was 4. Although concentrations of sTM, vWf, sP-selectin and sVCAM-1 were significantly elevated in SLE compared with values in healthy controls, they did not differ between the four groups, between patients with or without history of thrombosis, and between patients with or without LAC. Presence of anticardiolipin antibodies could not explain these negative findings. Adjustment of the concentrations for significantly associated variables, such as age, hypertension, smoking, immunosuppressive treatment and concentrations of creatinine, cholesterol and homocysteine, did not change the main results of the study. Only sTM was significantly lower in patients with both LAC and thrombosis than in patients without both these features after adjustment for serum creatinine concentrations. In conclusion, we did not find an association between endothelial cell activation and presence of LAC or history of thrombosis in SLE.Keywords
This publication has 39 references indexed in Scilit:
- Soluble Adhesion Molecules Reflect Endothelial Cell Activation in Ischemic Stroke and in Carotid AtherosclerosisStroke, 1997
- Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysisLupus, 1997
- Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β2‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2‐Glycoprotein I and Induce Endothelial ActivationArthritis & Rheumatism, 1997
- ENDOTHELIUM-DERIVED HAEMOSTATIC FACTORS AND THE ANTIPHOSPHOLIPID SYNDROMERheumatology, 1995
- Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosusInternational Journal of Cardiology, 1994
- CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITISRheumatology, 1994
- Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective studyClinical and Experimental Immunology, 1994
- STIMULATION OF VON WILLEBRAND FACTOR ANTIGEN RELEASE BY IMMUNOGLOBULIN FROM THROMBOSIS PRONE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THE ANTIPHOSPHOLIPID SYNDROMERheumatology, 1993
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982